REGENXBIO Cash on Hand 2014-2022 | RGNX

REGENXBIO cash on hand from 2014 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
REGENXBIO Annual Cash on Hand
(Millions of US $)
2021 $457
2020 $476
2019 $296
2018 $320
2017 $161
2016 $90
2015 $114
2014 $1
2013 $1
REGENXBIO Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $394
2021-12-31 $457
2021-09-30 $340
2021-06-30 $375
2021-03-31 $441
2020-12-31 $476
2020-09-30 $242
2020-06-30 $269
2020-03-31 $279
2019-12-31 $296
2019-09-30 $332
2019-06-30 $341
2019-03-31 $285
2018-12-31 $320
2018-09-30 $373
2018-06-30 $286
2018-03-31 $230
2017-12-31 $161
2017-09-30 $167
2017-06-30 $162
2017-03-31 $146
2016-12-31 $90
2016-09-30 $92
2016-06-30 $94
2016-03-31 $101
2015-12-31 $114
2015-09-30 $213
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2013-12-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.106B $0.470B
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00